<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Surgery and Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Surgery and Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Хирургия и онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="electronic">2949-5857</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">796</article-id><article-id pub-id-type="doi">10.17650/2949-5857-2025-15-4-82-86</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Perivascular epithelioid cell tumors: treatment characteristics. Clinical observation and literature review</article-title><trans-title-group xml:lang="ru"><trans-title>Опухоли из периваскулярных эпителиоидных клеток: особенности лечения. Клиническое наблюдение и обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-9885-0106</contrib-id><name-alternatives><name xml:lang="en"><surname>Mefodovskiy</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Мефодовский</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>virko-viktor@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6028-6210</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhuravlev</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Журавлев</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>virko-viktor@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-6101-476X</contrib-id><contrib-id contrib-id-type="spin">3900-8887</contrib-id><name-alternatives><name xml:lang="en"><surname>Virko</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Вирко</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>virko-viktor@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-4793-1670</contrib-id><name-alternatives><name xml:lang="en"><surname>Mefodovskiy</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Мефодовский</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>virko-viktor@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0240-6656</contrib-id><name-alternatives><name xml:lang="en"><surname>Lebedinets</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Лебединец</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>virko-viktor@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">S.M. Kirov Military Medical Academy, Ministry of Defense of Russia</institution></aff><aff><institution xml:lang="ru">ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Leningrad Regional Clinical Hospital</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Ленинградская областная клиническая больница»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-12-21" publication-format="electronic"><day>21</day><month>12</month><year>2025</year></pub-date><volume>15</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>82</fpage><lpage>86</lpage><history><date date-type="received" iso-8601-date="2025-05-20"><day>20</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Mefodovskiy M.A., Zhuravlev A.A., Virko V.A., Mefodovskiy A.A., Lebedinets A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Мефодовский М.А., Журавлев А.А., Вирко В.А., Мефодовский А.А., Лебединец А.А.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Mefodovskiy M.A., Zhuravlev A.A., Virko V.A., Mefodovskiy A.A., Lebedinets A.A.</copyright-holder><copyright-holder xml:lang="ru">Мефодовский М.А., Журавлев А.А., Вирко В.А., Мефодовский А.А., Лебединец А.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://onco-surgery.info/jour/article/view/796">https://onco-surgery.info/jour/article/view/796</self-uri><abstract xml:lang="en"><p>The article presents a clinical case of treatment of metastatic perivascular epithelioid tumor (PEComa) without a primary lesion in a 34-year-old woman who complained of a tumor on the anterior surface of the chest. The most effective class of drugs, mTOR inhibitors, was chosen to treat the neoplasm. However, in the presented clinical case, when treated with mTOR inhibitor everolimus as the first therapy line, disease progression was detected after the first control examination (after 5 months). The use of a drug from the group of protein kinase inhibitors, sorafenib, in the second line of treatment allowed to achieve remission within 9 months without tumor progression. To study the issue of the most effective methods of treating malignant mesenchymal tumors, an additional analysis of the scientific literature over the past 10 years was performed. Scientific databases such as PubMed and eLibrary were used to search and select literature. The search was conducted using the following keywords: “PEComas”, “PEComa treatment”, “chemotherapy for PEComa”, “perivascular epithelioid cell tumor”, “previous chemotherapy”.</p></abstract><trans-abstract xml:lang="ru"><p>В статье представлен клинический случай лечения метастатической опухоли из периваскулярных эпителиоидных клеток (ПЭКомы) без выявленного первичного очага у женщины 34 лет, которая обратилась с жалобами на образование на передней поверхности грудной клетки. Для лечения новообразования был выбран наиболее эффективный класс препаратов – mTOR-ингибиторы. Однако в представленном клиническом случае при лечении mTOR-ингибитором эверолимусом в качестве 1-й линии терапии после 1-го контрольного обследования (через 5 мес) выявлено прогрессирование заболевания. Применение во 2-й линии лечения препарата из группы ингибиторов протеинкиназ сорафениба позволило достигнуть ремиссии в течение 10 мес без прогрессии опухоли. Для изучения вопроса о наиболее эффективных методах лечения злокачественных мезенхимальных опухолей дополнительно проведен анализ научной литературы за последние 10 лет. Для поиска и отбора источников литературы использовали базы данных PubMed и eLibrary. Поиск вели по следующим ключевым словам: ПЭКомы, особенности лечения ПЭКом, химиотерапевтическое лечение ПЭКом, perivascular epithelioid cell neoplasm, pecoma, previous chemotherapy.</p></trans-abstract><kwd-group xml:lang="en"><kwd>perivascular epithelioid tumor</kwd><kwd>PEComa</kwd><kwd>characteristics of PEComa treatment</kwd><kwd>PEComa chemotherapy</kwd><kwd>PEComa treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>периваскулярная эпителиоидноклеточная опухоль</kwd><kwd>ПЭКома</kwd><kwd>особенности лечения ПЭКомы</kwd><kwd>химиотерапевтическое лечение ПЭКомы</kwd><kwd>лечение ПЭКомы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Yemel’yanov V.N., Kuzin A.A., Panin I.S., Kulemin M.E. Epidemiological monitoring of morbidity and mortality rates and the reliability of accounting for germinogenic testicular tumors. Vestnik Rossiyskoy voyenno-meditsinskoy akademii = Bulletin of the Russian Military Medical Academy 2025;27(1):115–24. (In Russ.). DOI: 10.17816/brmma632060</mixed-citation><mixed-citation xml:lang="ru">Емельянов В.Н., Кузин А.А., Панин И.С., Кулемин М.Э. Эпидемиологический мониторинг показателей заболеваемости, смертности и достоверность учета герминогенных опухолей яичка. Вестник Российской военно-медицинской академии 2025;27(1):115–24. DOI: 10.17816/brmma632060</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Armah H.B., Parwani A.V. Perivascular epithelioid cell tumor. Arch Pathol Lab Med 2009;133(4):648–54. DOI: 10.5858/133.4.648</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bennet J.A. Perivascular epithelioid cell tumor (PEComa) Available at: https://www.pathologyoutlines.com/topic/uteruspecoma.html</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zhang S., Chen F., Huang X. et al. Perivascular epithelial cell tumor (PEComa) of the pancreas: a case report and review of literature. Medicine (Baltimore) 2017;96(22):e7050. DOI: 10.1097/MD.0000000000007050</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Doyle L.A. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer 2014;120(12):1763–74. DOI: 10.1002/cncr.28657</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Nechushkina I.V. Pecoms. Onkopediatriya = Oncopediatrics 2016;3(4):267–76. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Нечушкина И.В. Пекомы. Онкопедиатрия 2016;3(4):267–76.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><mixed-citation>Hindi N., Sanfilippo R., Stacchiotti S. et al. 1450P – systemic therapy in perivascular epithelioid cell tumors (PEComa). Ann Oncol 2014;25(4):iv506–iv506. DOI: 10.1093/annonc/mdu354.39</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mehren M., Kane J.M. III, Benjamin R.S. et al. Soft tissue sarcoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20(7):815–33. DOI: 10.6004/jnccn.2022.0035</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Schoolmeester J.K., Dao L.N., Soslow R.A. TFE3 translocation associated perivascular epithelial cell tumor (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol 2015;39(3):394–404. DOI: 10.1097/PAS.0000000000000349</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Casali P.G., Abecassis N., Bauer S. et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(4):iv51–iv67. DOI: 10.1093/annonc/mdy096</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Gao F., Huang C., Zhang Y. et al. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive uterine PEComa. Cancer Biol Ther 2016;17(6):595–8. DOI: 10.1080/15384047.2016.1167290</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Le P., Garg A., Brandao G. et al. Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma. Curr Oncol 2014;21(3):e518–20. DOI: 10.3747/co.21.1849</mixed-citation></ref></ref-list></back></article>
